Page 1 of 1

Postmenopausal breast cancer: role of bisphosphonates

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well. The effect of Zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast...
Read Article

Osteoporosis: Alendronate may be associated with atrial fibrillation

Alendronate ( Fosamax ), a medication used to prevent fractures in women with osteoporosis, may be associated with an increased risk of atrial fibrillation. Other recent studies have reported atrial fibrillation as an unexpected adverse effect of bisphosphonates, a class of drugs that includes Al...
Read Article

Renal impairment associated with Zoledronic acid

There is a well-known risk of deterioration in renal function with intravenous bisphosphonates administered at a rapid infusion rate. ADRAC ( Adverse Drug Reactions Advisory Committee ) has received few reports of renal impairment or failure with Pamidronate ( Aredia ) and the oral bisphosphonates...
Read Article

Osteonecrosis of the jaw linked to use of bisphosphonates

Most of the cases of osteonecrosis of the jaw are seen in oncology patients that, besides intravenous bisphosphonates, have received chemotherapy in the long term for their base disease with or without intermittent cycles of steroids. Mechanism of action begins to be recognized, the bisphosphon...
Read Article

Alendronate impairs the action of Teriparatide to increase bone turnover in men

Alendronate ( Fosamax ) reduces the ability of Teriparatide ( Forteo / Forsteo ) to increase bone mineral density ( BMD ) in osteoporotic men. Researchers have evaluated whether Teriparatide increases osteoblast activity when the ability of Teriparatide to increase osteoclast activity is suppress...
Read Article

Osteoporosis: Forteo not cost-effective compared with Fosamax

Researchers at the Stanford University School of Medicine have found that a new osteoporosis drug, called Teriparatide ( Forteo ), is not cost-effective compared with the most commonly prescribed osteoporosis medication, Alendronate ( Fosamax ). While the average wholesale price of alendronate is...
Read Article

Denosumab shows increased bone mineral density in postmenopausal women

Twice-yearly subcutaneous injections of Denosumab ( 60 mg ) increased bone mineral density ( BMD ) in the lumbar spine, total hip, distal 1/3 radius and total body compared to placebo at 24 months. The ongoing, multi-center, phase 2 dose-ranging trial includes results from 337 healthy postmenopau...
Read Article

Prevention of secondary osteoporotic fractures in post menopausal women

The National Institute for Clinical Excellence ( NICE ) has issued guidance to the NHS in England and Wales on the use of bisphosphonates ( Alendronate, Etidronate, Risedronate ), Raloxifene and Teriparatide for the prevention of further osteoporotic fragility fractures in postmenopausal women who h...
Read Article

ADRAC : bisphosphonates and osteonecrosis of the jaw

Bisphosphonates are drugs commonly used to prevent and treat osteoporosis in post-menopausal women. They are widely used in the management of advanced cancers that have metastasized to the bone, where the disease often causes bone pain and possibly even fractures. Several cancers can metastasi...
Read Article